Background Pazopanib and sunitinib provided a progression-free survival benefit, as
compared with placebo or interferon, in previous phase 3 studies involving patients with …

Purpose Pazopanib is an oral angiogenesis inhibitor targeting vascular endothelial growth
factor receptor, platelet-derived growth factor receptor, and c-Kit. This randomized, double …

Abstract The von Hippel-Lindau (VHL) gene is often inactivated in sporadic renal cell
carcinoma (RCC) by mutation or promoter hypermethylation. The prognostic or predictive …

BACKGROUND: In this randomised phase III study (VEG105192; NCT00334282),
pazopanib previously demonstrated statistically and clinically meaningful improvement of …

Differentiating renal oncocytoma from its renal cell carcinoma (RCC) mimics, particularly
chromophobe RCC, can be difficult, especially when limited tissue is available for evaluation …

To test the effect of the exposure to trichloroethylene (TCE) on renal cell cancer (RCC) risk, a
case–control study was performed in the Arve Valley (France), a geographic area with a …

MicroRNAs regulate post-transcriptomic landscape in many tumors including renal cell
carcinoma. We have recently shown significantly increased expression of miR-21 in renal …

OBJECTIVE: To compare the characteristics and predictors of cancer-specific survival (CSS)
of 2 rare distal nephron tumors—medullary renal cell carcinoma (MRCC) and collecting duct …

Renal cell carcinoma (RCC) is the most common primary cancer arising from the kidney in
adults, with clear cell renal cell carcinoma (ccRCC) representing approximately 75% of all …

The first case of TFEB‐amplified renal cell carcinoma was published in 2014. Since then, 29
additional cases have been described. The prognostic and therapeutic implications of this …